Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Week in Review

Summaries of each week's events in China biotech are provided free to all readers.  A weekly email newsletter providing direct links to these articles is also available - click here for free email newsletter...

Week in Review: BioKangtai Acquires China Rights to AstraZeneca's COVID-19 Vaccine

Week in Review: Shanghai Hansoh Enters $68 Million Deal for Leukemia Candidate

Week in Review: BeiGene Signs $540 Million Deal for China Rights to Three HBV Candidates

Week in Review: China Life Science Announces $5 Billion in Deals, a Weekly Record

Week in Review: Ocumension Climbs to $2.5 Billion Market Cap after $184 Million Hong Kong IPO

Upcoming event
August 25-27, 2020
China Standard Time
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China